SEARCH

SEARCH BY CITATION

References

  • 1
    Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Int Med. 1997;157(21):24132446.
  • 2
    Office of Public Health and Science. Healthy People 2010 Objectives. Washington , DC : US Department of Health and Human Services; 2000.
  • 3
    Meissner I, Whisnant JP, Sheps SG, et al. Detection and control of high blood pressure in the community: do we need a wake-up call? Hypertension. 1999;34(3):466471.
  • 4
    Hyman DJ, Pavlik VN. Characteristics of patients with uncontrolled hypertension in the United States. N Engl J Med. 2001;345(7):479486.
  • 5
    American Diabetes Association. Standards of medical care for patients with diabetes. Diabetes Care. 2001;24(suppl 1):S1S133.
  • 6
    Bakris GL, Williams M, Dworkin L, et al. Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis. 2000;35:646661.
  • 7
    Laragh J. Treatment of hypertension is a worldwide failure. Am J Hypertens. 2001;14:8489.
  • 8
    Trilling JS, Froom J. The urgent need to improve hypertension care. Arch Fam Med. 2000;9(9):794801.
  • 9
    Chobanian AV. Control of hypertension—an important national priority. N Engl J Med. 2001;345(7):534535.
  • 10
    Carter BL. Management of essential hypertension. In: BertchK, DunsworthT, FaganS, et al., eds. The Pharmacotherapy Self-Assessment Program. 4th ed. Kansas City , MO : The American College of Clinical Pharmacy; 2001.
  • 11
    ASHP Residency Directory. Accessed Nov. 28, 2001. http:www.ashp.orgdirectoriesresidency.
  • 12
    Roster of residents completing ASHP-accredited programs in calendar year 2001. Am J Health Syst Pharm. 2001;58: 12351244.
  • 13
    Board of Pharmaceutical Specialties Home Page. Accessed October 10, 2001. www.bpsweb.org.
  • 14
    Department of Health and Human Services, Bureau of Health Professions. Report to Congress: The Pharmacist Workforce: A Study of the Supply and Demand for Pharmacists. Washington , DC : Government Printing Office; 2000.
  • 15
    Knapp KK, Paavola FG, Maine LL, et al. Availability of primary care providers and pharmacists in the United States. J Am Pharm Assoc. 1999;39(2):127135.
  • 16
    Alsuwaidan S, Malone DC, Billups SJ, et al. Characteristics of ambulatory care clinics and pharmacists in Veterans Affairs medical centers. Impact of Managed Pharmaceutical Care on Resource Utilization and Outcomes in Veterans Affairs Medical Centers, IMPROVE investigators. Am J Health Syst Pharm. 1998;55(1):6872.
  • 17
    Carter BL, Helling DK. Ambulatory care pharmacy services: has the agenda changed? Ann Pharmacother. 2000; 34(6):772787.
  • 18
    McKenney JM, Slining JM, Henderson HR, et al. The effect of clinical pharmacy services on patients with essential hypertension. Circulation. 1973;48(5):11041011.
  • 19
    McKenney JM, Brown ED, Necsary R, et al. Effect of pharmacist drug monitoring and patient education on hypertensive patients. Contemp Pharm Pract. 1978;1:5056.
  • 20
    Park JJ, Kelly P, Carter BL, et al. Comprehensive pharmaceutical care in the chain setting. J Am Pharm Assoc. 1996; 36(7):443451.
  • 21
    Carter BL, Barnette DJ, Chrischilles E, et al. Evaluation of hypertensive patients after care provided by community pharmacists in a rural setting. Pharmacotherapy. 1997; 17(6):12741275.
  • 22
    Monane M, Matthias DM, Nagle BA, et al. Improving prescribing patterns for the elderly through an online drug utilization review intervention: a system linking the physician, pharmacist, and computer. JAMA. 1998;280(14): 12491252.
  • 23
    Raisch DW. A model of methods for influencing prescribing: Part II. A review of educational methods, theories of human inference, and delineation of the model. Drug Intell Clin Pharm. 1990;24(5):537542.
  • 24
    Baran RW, DuChane J, Parker L, et al. Effectiveness of academic detailing in the managed care environment: improving prescribing of lipid-lowering agents. J Managed Care Pharm. 1996;2:148157.
  • 25
    Bero LA, Grilli R, Grimshaw JM, et al. Closing the gap between research and practice: an overview of systematic reviews of interventions to promote the implementation of research findings. The Cochrane Effective Practice and Organization of Care Review Group. BMJ. 1998; 317(7156):465468.
  • 26
    Davis DA, Thomson MA, Oxman AD, et al. Evidence for the effectiveness of CME. A review of 50 randomized controlled trials. JAMA. 1992;268(9):11111117.
  • 27
    O'Connell DL, Henry D, Tomlins R. Randomised controlled trial of effect of feedback on general practitioners' prescribing in Australia. BMJ. 1999;318(7182):507511.
  • 28
    Soumerai SB, Avorn J. Principles of educational outreach (‘academic detailing’) to improve clinical decision making. JAMA. 1990;263(4):549556.
  • 29
    Van Eijk ME, Avorn J, Porsius AJ, et al. Reducing prescribing of highly anticholinergic antidepressants for elderly people: randomised trial of group versus individual academic detailing. BMJ. 2001;322(7287):654657.
  • 30
    Headrick LA, Speroff T, Pelecanos HI, et al. Efforts to improve compliance with the National Cholesterol Education Program guidelines. Results of a randomized controlled trial. Arch Intern Med. 1992;152(12): 24902496.
  • 31
    Lipton HL, Byrns PJ, Soumerai SB, et al. Pharmacists as agents of change for rational drug therapy. Int J Technol Assess Health Care. 1995;11(3):485508.
  • 32
    Eisenberg JM. Doctors' Decisions and the Cost of Medical Care. Ann Arbor , MI : Health Administration Press Perspectives; 1986.
  • 33
    Lin EH, Katon WJ, Simon GE, et al. Achieving guidelines for the treatment of depression in primary care: is physician education enough? Med Care. 1997;35(8):831842.
  • 34
    Soumerai SB, McLaughlin TJ, Avorn J. Quality assurance for drug prescribing. Qual Assur Health Care. 1990;2(1):3758.
  • 35
    Knowles MS. Self-Directed Learning: A Guide for Learners and Teachers. New York , NY : The Adult Education Company; 1975.
  • 36
    Elliott TE, Elliott BA. Physician acquisition of cancer pain management knowledge. J Pain Symptom Manage. 1991; 6(4):224229.
  • 37
    Elliott TE, Murray DM, Oken MM, et al. Improving cancer pain management in communities: main results from a randomized controlled trial. J Pain Symptom Manage. 1997;13(4):191203.
  • 38
    McGhan WF, Stimmel GL, Hall TG, et al. A comparison of pharmacists and physicians on the quality of prescribing for ambulatory hypertensive patients. Med Care. 1983; 21(4):435444.
  • 39
    Monson R, Bond CA, Schuna A. Role of the clinical pharmacist in improving drug therapy. Clinical pharmacists in outpatient therapy. Arch Intern Med. 1981;141(11):14411444.
  • 40
    Bond CA, Monson R. Sustained improvement in drug documentation, compliance, and disease control. A four-year analysis of an ambulatory care model. Arch Intern Med. 1984;144(6):11591162.
  • 41
    Solomon DK, Portner TS, Bass GE, et al. Clinical and economic outcomes in the hypertension and COPD arms of a multicenter outcomes study. J Am Pharm Assoc. 1998;38(5):574585.
  • 42
    Hawkins DW, Fiedler FP, Douglas HL, et al. Evaluation of a clinical pharmacist in caring for hypertensive and diabetic patients. Am J Hosp Pharm. 1979;36(10):13211325.
  • 43
    Morse GD, Douglas JB, Upton JH, et al. Effect of pharmacist intervention on control of resistant hypertension. Am J Hosp Pharm. 1986;43(4):905909.
  • 44
    Erickson SR, Slaughter R, Halapy H. Pharmacists' ability to influence outcomes of hypertension therapy. Pharmacotherapy. 1997;17(1):140147.
  • 45
    Mehos BM, Saseen JJ, MacLaughlin EJ. Effect of pharmacist intervention and initiation of home blood pressure monitoring in patients with uncontrolled hypertension. Pharmacotherapy. 2000;20(11):13841389.
  • 46
    Bogden PE, Abbott RD, Williamson P, et al. Comparing standard care with a physician and pharmacist team approach for uncontrolled hypertension. J Gen Intern Med. 1998;13(11):740745.
  • 47
    Chrischilles EA, Helling DK, Rowland CR. Model for cost-benefit analysis of clinical pharmacy in family practice. Am J Hosp Pharm. 1982;39(6):992998.
  • 48
    Chrischilles EA, Helling DK, Rowland CR. Clinical pharmacy services in family practice: cost-benefit analysis. II. Referrals, appointment compliance, and costs. Drug Intell Clin Pharm. 1984;18(5):436441.
  • 49
    Chrischilles EA, Helling DK, Rowland CR. Clinical pharmacy services in family practice: cost-benefit analysis. I. Physician time and quality of care. Drug Intell Clin Pharm. 1984;18(4):333341.
  • 50
    Chrischilles EA, Helling DK, Rowland CR. Cost-benefit analysis of clinical pharmacy services in three Iowa family practice offices. J Clin Hosp Pharm. 1985;10(1):5966.
  • 51
    Leape LL, Cullen DJ, Clapp MD, et al. Pharmacist participation on physician rounds and adverse drug events in the intensive care unit. JAMA. 1999;282(3):267270.
  • 52
    Bond CA, Raehl CL, Franke T. Medication errors in United States hospitals. Pharmacotherapy. 2001;21(9):10231036.
  • 53
    Carter BL, Helling DK, Jones ME, et al. Evaluation of family physician prescribing: influence of the clinical pharmacist. Drug Intell Clin Pharm. 1984;18(10):817821.
  • 54
    Brown DJ, Helling DK, Jones ME. Evaluation of clinical pharmacist consultations in a family practice office. Am J Hosp Pharm. 1979;36(7):912915.
  • 55
    Haxby DG, Weart CW, Goodman BWJr. Family practice physicians' perceptions of the usefulness of drug therapy recommendations from clinical pharmacists. Am J Hosp Pharm. 1988;45(4):824827.